Overview

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-12
Target enrollment:
Participant gender:
Summary
Phase 3 placebo-controlled trial to determine efficacy of the probiotic LGG for reducing acute treatment related GI toxicity in patients with GI malignancy with phase 1 safety lead-in.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine